BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dr. Reddy's Laboratories Ltd. (RDY) Signs Definitive Agreement With 3i For The Strategic Acquisition Of Betapharm Arzneimittel GmbH For Up To $572 Million


2/16/2006 10:31:42 AM

HYDERABAD, India & FRANKFURT, Germany & AUGSBURG, Germany--(BUSINESS WIRE)--Feb. 16, 2006--Dr. Reddy's Laboratories (NYSE: RDY): betapharm is the fourth-largest generics company in Germany and the fastest growing company in the top 10(1). Combination of Dr. Reddy's and betapharm offers an excellent opportunity to build on the unique strengths of each company to emerge as a leading generics player in Europe in the long- term. Dr. Reddy's and 3i, Europe's leading private equity house, jointly announced today that they have entered into a definitive agreement providing for the strategic investment by Dr. Reddy's to acquire 100% of betapharm Group, the fourth-largest generic pharmaceuticals company in Germany, for a total enterprise value of EUR 480 million in cash. The transaction will be funded using a combination of Dr. Reddy's internal cash reserves and committed credit facilities.

Read at BioSpace.com
Read at Reuters

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES